Dyskinesia is a broad medical term for involuntary, uncontrollable movements that a person cannot stop on their own. The word comes from Greek roots meaning “abnormal movement,” and it covers everything from slow writhing motions to rapid jerking or twisting. Dyskinesia is not a single disease but rather a symptom that shows up across many neurological conditions and, commonly, as a side effect of certain medications. The specific pattern of movement, where it appears on the body, and what triggers it all matter for figuring out the cause and deciding on treatment.
What Dyskinesia Actually Looks Like
Because “dyskinesia” is an umbrella term, the movements it describes vary widely. Some people experience quick, dance-like jerking in their limbs or face. Others have slow, twisting postures that lock a hand or foot into an uncomfortable position. Still others deal with repetitive motions of the tongue, jaw, or lips that they can feel but cannot suppress. The movements can affect one body region or several at once, and they range from barely noticeable to severe enough to interfere with walking, eating, or speaking.
The experience is not just physical. In a survey of people with tardive dyskinesia in the United States, the average psychological impact score was higher than the physical impact score, and over two-thirds of patients reported being bothered by negative reactions from others, including staring, jokes, and being told to stop moving.
The Main Types of Involuntary Movement
Clinicians classify dyskinesia by the character of the movement itself. These categories overlap in practice, and a single person can display more than one type at different times or even simultaneously.
- Chorea: An ongoing sequence of brief, irregular movements that appear random, jumping unpredictably from one body part to another. It can look like fidgeting or restlessness.
- Athetosis: Slow, continuous writhing that prevents a person from holding a stable posture, often most visible in the hands and fingers.
- Dystonia: Sustained or intermittent muscle contractions that force a body part into an abnormal, sometimes painful, posture.
- Ballism: Large, flinging movements of the arms or legs, essentially a more violent cousin of chorea.
- Tremor: Rhythmic, back-and-forth shaking, which differs from the others in being regular and predictable rather than random.
Chorea and athetosis often blend together and may be called “choreoathetosis.” Dystonia frequently coexists with other movement types as well.
Levodopa-Induced Dyskinesia in Parkinson’s Disease
The most common context where people encounter the word “dyskinesia” is Parkinson’s disease. Levodopa, the gold-standard medication for Parkinson’s, replaces the dopamine that dying brain cells can no longer produce. It works well for stiffness and slowness, but over months or years many patients develop involuntary movements as a side effect. These movements tend to be choreic, affecting the trunk, limbs, head, or face, and they emerge as the brain’s response to dopamine replacement becomes increasingly erratic.
Research points to changes in how dopamine receptors on brain cells respond over time. Rather than the receptors themselves increasing in number, their individual sensitivity ramps up, particularly in the “direct pathway” that normally helps initiate wanted movements. When a dose of levodopa floods those hypersensitive receptors, the result is an overshoot: movements the person did not intend.
Levodopa-induced dyskinesia falls into three recognized patterns, each tied to the timing of a medication dose:
- Peak-dose dyskinesia: Involuntary movements that appear when levodopa levels in the blood are highest, usually choreic in character.
- Off-period dystonia: Painful cramping or twisting, often in the feet, that shows up when medication levels drop too low, such as early in the morning before the first dose.
- Diphasic dyskinesia: Movements that flare as levodopa is kicking in and again as it is wearing off, but quiet down during the peak. These tend to be more dystonic and can involve the legs more than the arms.
Research using deep brain stimulation to probe the brain’s subthalamic nucleus has shown that these three patterns likely represent a continuous spectrum of the same underlying neural activity rather than entirely separate conditions.
Tardive Dyskinesia From Psychiatric and Gastrointestinal Medications
Tardive dyskinesia, often called TD, is a distinct form that develops after prolonged use of drugs that block dopamine receptors. The word “tardive” means delayed or late-appearing, and that is the hallmark: TD typically shows up months or years after the medication was started, sometimes even after it has been stopped. The movements are most recognizable in the face, where they cause repetitive lip smacking, tongue protrusion, chewing motions, or grimacing. They can also involve the limbs and trunk.
The biggest culprits are antipsychotic medications, particularly older “first-generation” drugs like haloperidol. Newer antipsychotics carry a lower but still real risk. What surprises many people is that TD can also result from drugs used for entirely non-psychiatric reasons. Metoclopramide, widely prescribed for nausea and slow stomach emptying, is a dopamine-blocking drug. Regulatory agencies have placed restrictions on its long-term use because of TD risk, and in the United States the drug carries a black-box warning specifically about tardive dyskinesia.
The exact mechanism behind TD remains debated. Three leading theories have been proposed: dopamine receptor supersensitivity from chronic blockade, oxidative stress damaging brain cells, and abnormal rewiring of brain connections. A primate study found that a specific dopamine receptor subtype, D3, was upregulated in the brain region controlling movement in animals that developed TD after haloperidol exposure, while D2 receptors remained at normal levels. That finding added nuance to the older “supersensitivity” theory, which had focused mainly on D2 receptors.
How the Brain’s Movement Circuits Go Wrong
To understand why dyskinesia happens, it helps to know that the brain has a built-in system for selecting which movements get executed and which get suppressed. A cluster of deep brain structures called the basal ganglia acts as a gatekeeper. One pathway through this circuit promotes a desired movement by releasing the brakes on the brain’s motor areas. A separate pathway applies the brakes to suppress competing, unwanted movements. In a healthy brain, these two pathways stay in balance, letting you reach for a coffee cup without your other hand flailing or your leg kicking.
Dyskinesia emerges when this balance tips. In Parkinson’s, dopamine loss makes the suppression pathway overactive, leading to the slowness and rigidity of the disease. Levodopa corrects that but can overcorrect the promotion pathway, tipping the balance toward too much movement. In TD, chronic dopamine blockade triggers compensatory changes in the same circuits. The specifics differ, but the common thread is a disruption of the brain’s ability to cleanly select wanted movement and inhibit everything else.
Less Common Causes
Genetic Dyskinesias
Some forms of dyskinesia are inherited rather than drug-induced. Paroxysmal kinesigenic dyskinesia, caused by mutations in the PRRT2 gene, triggers brief attacks of involuntary movement set off by sudden motion, like standing up quickly. These episodes usually last seconds to minutes and respond well to anticonvulsant medications. Research now classifies PRRT2-related conditions as synaptopathies, meaning disorders of how nerve cells communicate at synapses, rather than ion channel problems as was previously assumed.
Mutations in the ADCY5 gene cause a different pattern: early-onset chorea, dystonia, and episodes of intense involuntary movement that can start in infancy or early childhood. These genetic causes are rare individually, but collectively they remind clinicians that not every case of dyskinesia traces back to a medication.
Autoimmune and Post-Infectious Causes
The immune system can sometimes target brain structures involved in movement. Sydenham chorea, which follows strep throat infections in children, is the classic example: the body’s antibodies against streptococcal bacteria mistakenly attack the basal ganglia. The related PANDAS spectrum extends this concept to include dystonic and myoclonic variants that appear after streptococcal infection.
Beyond strep-related conditions, autoimmune encephalitis caused by antibodies against the NMDA receptor can produce involuntary movements alongside psychiatric symptoms, seizures, and cognitive changes. A growing list of other antibody-mediated conditions can trigger movement abnormalities in both children and adults.
Dyskinesia in Children
Dyskinesia in children deserves separate attention because the causes and presentations often differ from those in adults. While Parkinson’s disease and antipsychotic exposure are the leading triggers in older adults, children more commonly develop dyskinesia from autoimmune conditions, genetic mutations, brain injury at birth (particularly affecting the basal ganglia), or metabolic disorders.
Classifying the specific type of involuntary movement in a child can be trickier than in adults, in part because children’s motor systems are still developing. A consensus effort to define and classify hyperkinetic movements in childhood noted that chorea, athetosis, dystonia, myoclonus, and tremor each have specific features that need to be distinguished, since the treatment approach differs significantly depending on the movement type.
How Dyskinesia Is Assessed
Diagnosing dyskinesia relies heavily on clinical observation. There is no blood test or brain scan that directly measures involuntary movements. A neurologist will watch the patient at rest and during activities, note the body regions affected, and characterize the type of movement. Video recording is standard practice, both for initial assessment and for tracking changes over time.
For levodopa-induced dyskinesia specifically, the Unified Dyskinesia Rating Scale (UDysRS) has become the standard measurement tool since its publication in 2008. It covers four domains: the patient’s own perception of how on-dyskinesia affects daily life, the impact of off-period dystonia, an objective rating of movement severity across seven body regions, and observed disability during specific tasks.
Clinically meaningful improvement on the UDysRS corresponds to roughly an 8-to-10-point drop in total score. A decrease of about 9 to 10 points corresponds to at least 30 fewer minutes per day of troublesome dyskinesia as reported in patient diaries, which gives a sense of what those numbers mean in daily life.
For tardive dyskinesia, the Abnormal Involuntary Movement Scale (AIMS) is more commonly used. It rates movements in the face, extremities, and trunk on a severity scale. Both tools depend on skilled observation, which is one reason that people with dyskinesia are often referred to movement disorder specialists rather than assessed only by general practitioners.
Treatment for Levodopa-Induced Dyskinesia
Managing levodopa-induced dyskinesia usually starts with adjusting the Parkinson’s medication itself. Lowering individual levodopa doses, giving them more frequently, or switching to extended-release formulations can smooth out the peaks and troughs in dopamine levels that drive the movements. Adding other Parkinson’s medications that work through different mechanisms can sometimes allow a lower levodopa dose while maintaining motor control.
When dose adjustments are not enough, amantadine is the main add-on drug. Originally developed as an antiviral, amantadine blocks a receptor called NMDA and has been the only medication with solid evidence for reducing levodopa-induced dyskinesia for years. A meta-analysis found that amantadine produced a significant reduction in dyskinesia severity, while other NMDA-targeting drugs tested in the same analysis did not show a clear benefit.
For patients whose dyskinesia remains disabling despite medication changes, deep brain stimulation (DBS) is an option. Electrodes are surgically implanted in specific brain targets and deliver continuous electrical pulses. Two targets are commonly used: the subthalamic nucleus (STN) and the globus pallidus internus (GPi). Both reduce dyskinesia, but a meta-analysis found that GPi stimulation offered a greater reduction in dyskinesia scores at one year compared to STN stimulation. A separate retrospective study put numbers on the difference: GPi-targeted DBS improved dyskinesia scores by roughly 94%, while STN-targeted DBS improved them by about 61%. STN stimulation, however, allowed a larger reduction in overall levodopa dosage, which matters because lower levodopa doses themselves reduce the stimulus for dyskinesia.
Treatment for Tardive Dyskinesia
TD has historically been one of the more frustrating conditions to treat. For decades, the main advice was to reduce or stop the offending medication when possible, which is not always feasible when the drug is managing a serious psychiatric illness. That changed with the approval of two drugs that inhibit a protein called VMAT2 (vesicular monoamine transporter 2), which controls how much dopamine is packaged and released by nerve cells.
Valbenazine and deutetrabenazine both reduce involuntary movements in TD. In a meta-analysis of randomized trials, both drugs significantly outperformed placebo at reducing AIMS scores. Valbenazine had a slightly larger effect and a lower number-needed-to-treat: roughly 4 patients need to take it for one to achieve at least a 50% improvement, compared to about 7 for deutetrabenazine. The two drugs differ in dosing schedule and side-effect profiles, which gives clinicians some flexibility in matching the treatment to the patient.
Even with these newer options, TD does not always resolve completely, and some patients experience a return of symptoms if the VMAT2 inhibitor is stopped. Prevention remains the best strategy: using the lowest effective dose of dopamine-blocking medications and monitoring regularly for early signs of involuntary movement.
The Social and Emotional Weight
Dyskinesia is visible in a way that many neurological symptoms are not, and that visibility carries consequences. A US survey of people with tardive dyskinesia found that over half reported strangers staring, asking intrusive questions, or making jokes at their expense. More than 70% said they were bothered by negative reactions from employers, coworkers, friends, and family members. The psychological impact scores in the survey were the highest of any domain, averaging 3.5 out of 5 and climbing to 4.0 in people with severe symptoms.
An experimental study reinforced these self-reports from a different angle. When participants were shown videos of people with TD movements and asked about their perceptions regarding employment, dating, and friendship potential, ratings were consistently more negative compared to videos of the same individuals without visible movements. The effect held for both mild-to-moderate and moderate-to-severe TD.
This stigma has practical consequences beyond hurt feelings. People may skip social events, avoid job interviews, or even stop taking needed psychiatric medication out of fear that the dyskinesia will worsen. Clinicians managing dyskinesia often need to address the emotional toll alongside the movement itself.
Physical Rehabilitation
Medication and surgery get most of the attention, but structured physical rehabilitation can also help. A pilot study comparing two rehabilitation programs in people with Parkinson’s-related dyskinesia found that both groups improved, but the group receiving a more intensive protocol saw particularly striking results: a 74% reduction in a dyskinesia rating scale and a 71% reduction in abnormal involuntary movement scores, compared to 10% and 8% in the group receiving a less intensive approach. These were small groups, so the precise numbers should be interpreted cautiously, but the direction of the finding supports the idea that targeted exercise and movement training have a role.
Rehabilitation for dyskinesia typically focuses on balance, coordination, and strategies to compensate for involuntary movements during daily tasks. For scapular dyskinesia, a condition where the shoulder blade moves abnormally during arm movement and which is mechanistically distinct from the neurological dyskinesias discussed above, structured physical and occupational therapy focused on motor relearning has been tested in a randomized trial as well. The term “dyskinesia” gets applied to both neurological involuntary movements and certain biomechanical problems like abnormal scapular motion, which can be confusing. If your doctor mentions dyskinesia in the context of a shoulder problem, they are usually talking about a movement pattern issue rather than a brain disorder.
When Dyskinesia Is Not What It Seems
Not every involuntary movement is what it first appears. Functional movement disorders produce real, disabling movements that look like dyskinesia but arise from altered brain-network processing rather than structural neurological damage or medication effects. These were once dismissed as “psychogenic,” but current understanding recognizes them as genuine neurological conditions that happen to require different treatment, typically specialized physiotherapy and psychological approaches rather than the drugs or surgeries used for organic dyskinesia.
Distinguishing functional movements from other dyskinesias matters because the treatment paths diverge sharply. Features that raise suspicion include movements that change character when the person is distracted, sudden onset without a clear trigger, and inconsistency in the affected body parts. A movement disorder specialist can usually make the distinction through careful examination, though it sometimes takes time and repeat visits. Getting this right early saves patients from unnecessary medications and their side effects.